Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Researchers Identify Drivers of Resistance to KRAS Inhibitors in Colorectal Cancer

A new preclinical study led by researchers at The University of Texas MD Anderson Cancer Center and Weill Cornell Medicine has uncovered genetic and cell-state adaptive mechanisms that drive resistance to KRAS inhibitors in patients with KRAS-mutant colorectal cancer. These findings suggest that targeting early inflammatory responses by adding TBK1 blockade with KRAS inhibition may be a promising combination strategy to overcome treatment resistance.

May 21, 2026


May 29 2026

May 28 2026

May 27 2026

May 26 2026

May 25 2026

May 22 2026

May 21 2026

May 20 2026

May 19 2026

May 18 2026

May 17 2026

May 16 2026